scholarly journals Effect of bevacizumab on brain radiation necrosis in anaplastic lymphoma kinase‐positive lung cancer

2019 ◽  
Vol 7 (7) ◽  
Author(s):  
Kengo Tanigawa ◽  
Keiko Mizuno ◽  
Yusuke Kamenohara ◽  
Taiji Unoki ◽  
Shunsuke Misono ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Anaplastic Lymphoma Kinase ◽  
Radiation Necrosis ◽  
Anaplastic Lymphoma ◽  
Brain Radiation Necrosis ◽  
Brain Radiation

scholarly journals Brain Radiation Necrosis: Current Management With a Focus on Non-small Cell Lung Cancer Patients

2018 ◽  
Vol 8 ◽  
Author(s):  
Gokoulakrichenane Loganadane ◽  
Frédéric Dhermain ◽  
Guillaume Louvel ◽  
Paul Kauv ◽  
Eric Deutsch ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Radiation Necrosis ◽  
Small Cell ◽  
Small Cell Lung ◽  
Current Management ◽  
Lung Cancer Patients ◽  
Brain Radiation Necrosis ◽  
Brain Radiation

Bevacizumab efficacy in treatment of brain radiation necrosis

2019 ◽  
Vol 1 (10) ◽  
pp. 15-21
Author(s):  
O. V. Absalyamova ◽  
G. L. Kobiakov ◽  
S. L. Gutorov ◽  
E. R. Vetlova ◽  
S. V. Zolotova ◽  
...  
Keyword(s):  
Adverse Effect ◽  
Vascular Endothelial Growth Factor ◽  
Arteriovenous Malformations ◽  
Radiation Necrosis ◽  
Critical Role ◽  
Common Adverse Effect ◽  
Vascular Endothelial ◽  
Brain Radiation Necrosis ◽  
Endothelial Growth Factor ◽  
Brain Radiation

Radiation therapy (RT) plays an important role in treatment of primary and metastatic CNS tumors and some non-neopiastic conditions (arteriovenous malformations, trigeminal neuralgia). Radiation necrosis (RN) is a common adverse effect of RT. Until recently steroid therapy was used as a main treatment regimen for RN. Mechanisms of RN development are not clear; however, it was shown that vascular endothelial growth factor (VEGF) plays a critical role in its formation. A number of surveys showed efficacy of bevacizumab as an anti-VEGF agent in treatment of RN. Radiation necrosis pathogenesis, diagnostics and treatment are summarized in this review.

scholarly journals Systematic Review and Network Meta-Analysis of Anaplastic Lymphoma Kinase (ALK) Inhibitors for Treatment-Naïve ALK-Positive Lung Cancer

Cancers ◽  
2021 ◽  
Vol 13 (8) ◽  
pp. 1966
Author(s):  
Cheng-Hao Chuang ◽  
Hsiao-Ling Chen ◽  
Hsiu-Mei Chang ◽  
Yu-Chen Tsai ◽  
Kuan-Li Wu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Brain Metastasis ◽  
Anaplastic Lymphoma Kinase ◽  
Low Dose ◽  
Meta Analysis ◽  
Phase Iii ◽  
Pairwise Comparisons ◽  
Anaplastic Lymphoma ◽  
Treatment Naïve ◽  
Alk Positive

Several anaplastic lymphoma kinase inhibitors (ALKIs) have demonstrated excellent efficacy on overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and also better adverse effect (AE) profiles compared to cytotoxic chemotherapy in advanced stage anaplastic lymphoma kinase (ALK) rearrangement-positive non-small cell lung cancer (NSCLC) in phase III randomized clinical trials (RCTs). We conducted this systematic review and network meta-analysis to provide a ranking of ALKIs for treatment-naïve ALK-positive patients in terms of PFS, ORR, and AEs. In addition, a sub-group analysis of treatment benefits in patients with baseline brain metastasis was also conducted. Contrast-based analysis was performed for multiple treatment comparisons with the restricted maximum likelihood approach. Treatment rank was estimated using the surface under the cumulative ranking curve (SUCRA), as well as the probability of being the best (Prbest) reference. All next-generation ALKIs were superior to crizotinib in PFS but lorlatinib and brigatinib had increased AEs. The probability of lorlatinib being ranked first among all treatment arms was highest (SUCRA = 93.3%, Prbest = 71.8%), although there were no significant differences in pairwise comparisons with high- (600 mg twice daily) and low- (300 mg twice daily) dose alectinib. In subgroup analysis of patients with baseline brain metastasis, low-dose alectinib had the best PFS (SUCRA = 87.3%, Prbest = 74.9%). Lorlatinib was associated with the best ranking for ORR (SUCRA = 90.3%, Prbest = 71.3%), although there were no significant differences in pairwise comparisons with the other ALKIs. In addition, low-dose alectinib had the best safety performance (SUCRA = 99.4%, Prbest = 97.9%). Lorlatinib and low-dose alectinib had the best PFS and ORR in the overall population and baseline brain metastasis subgroup, respectively. Low-dose alectinib had the lowest AE risk among the available ALKIs. Further head-to-head large-scale phase III RCTs are needed to verify our conclusions.

scholarly journals Disease Flare after Discontinuation of Crizotinib in Anaplastic Lymphoma Kinase-Positive Lung Cancer

2013 ◽  
Vol 6 (2) ◽  
pp. 430-433 ◽  
Author(s):  
Yuka Kuriyama ◽  
Young Hak Kim ◽  
Hiroki Nagai ◽  
Hiroaki Ozasa ◽  
Yuichi Sakamori ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Anaplastic Lymphoma Kinase ◽  
Disease Flare ◽  
Anaplastic Lymphoma
Sign in / Sign up

Export Citation Format

Share Document